pharmacie et médicaments – Accord sur prise en charge médicaments anti-PCSK9

This written question concerns the coverage of PCSK9 inhibitor drugs, a new class of cholesterol-lowering medications. It seeks clarification on the conditions and accessibility of these treatments. The question addresses patients who may benefit from these advanced therapies and the healthcare system's capacity to provide them.